Integrated ReportFiscal Year Ended Mar. 31, 2021
Our Company
Our Strategy
-
Sustainability
-
Four Key Components of Our Corporate Strategy
-
Message from the COO
-
Medical Business Strategy: Chinese Market
-
Medical Business Strategy: Strengthening Business Foundations and Corporate Portfolio
-
Reprocessing
-
Endoscopic Solutions Division
-
Therapeutic Solutions Division
-
Scientific Solutions Division
-
Message from the CTO
-
EVIS X1 Dialogue
-
Innovation Initiatives
-
Message from the CAO
-
Overview of Transform Olympus
-
Evolving Our Corporate Culture
Our Setup
-
Directors
-
Governance Roundtable Discussion
-
Corporate Governance
-
Risk Management
-
Information Security
-
Information Disclosure
Data
-
Global Healthcare Data
-
10-Year Financial/Non-financial Data
-
Overview of Operating Results and Others
-
Consolidated Financial Statements and Notes
-
Independent Auditor’s Report
-
Corporate Information/Stock Information
- FY Ended Mar. 31, 2025
- FY Ended Mar. 31, 2024
- FY Ended Mar. 31, 2023
- FY Ended Mar. 31, 2022
- FY Ended Mar. 31, 2021
- FY Ended Mar. 31, 2020
- FY Ended Mar. 31, 2019
- FY Ended Mar. 31, 2018
- FY Ended Mar. 31, 2017
- FY Ended Mar. 31, 2016
- FY Ended Mar. 31, 2015
- FY Ended Mar. 31, 2014
- FY Ended Mar. 31, 2013
- FY Ended Mar. 31, 2012